Hangzhou Diagens Biotechnology (HKG:2526) reported an attributable loss of 55.9 million yuan for the first half of 2026, widening from a loss of 1.3 million yuan a year earlier, according to a Hong Kong bourse filing on Friday.
The medical imaging products maker's loss per share swelled to 0.66 yuan from 0.02 yuan a year ago.
Revenue increased year on year to 108.7 million yuan from 89.8 million yuan.